Perioperative addition of nivolumab adds value in NSCLC

MedNet.nl: Adding immunotherapy in the form of nivolumab to neoadjuvant chemotherapy plus adjuvant treatment with nivolumab showed benefit in patients with untreated resectable non-small-cell lung cancer (NSCLC) in the CheckMate 77T trial. Patients have a better prognosis if preoperative treatment of lung cancer leads to a pathologic complete response than if clear cancer cells are still present in postoperative material. For example, neoadjuvant nivolumab plus chemotherapy in patients with resectable NSCLC has shown to be more effective than chemotherapy alone. The CheckMate 77T trial is evaluating the efficacy of adding perioperative nivolumab for the first time in a randomized phase 3 setting. Adults with untreated resectable stage IIA–IIIB NSCLC were stratified in the study based on tumor histology, PD-L1 expression, and disease stage, and randomized to nivolumab plus platinum-doublet chemotherapy (four cycles) followed by surgery and 1 year of adjuvant nivolumab, or placebo plus platinum-doublet chemotherapy (four cycles) followed by surgery and 1 year of adjuvant placebo. After a follow-up of at least 15.7 months, nivolumab plus chemotherapy was found to improve event-free survival (EFS), the primary endpoint of the study, compared with placebo plus chemotherapy plus (median not reached vs 18.4 months; p=0.00025). Grade 3–4 treatment-related adverse events occurred in 32% and 25% of patients in the nivolumab and placebo arms, respectively, and surgery-related adverse events in 12% and 12% of patients, respectively. Cascone T, et al. CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II-IIIb NSCLC. ESMO 2023, abstract LBA1. This article was originally published in Dutch on MedNet.nl

ERS Congress 2024

Springer Medicine

Perioperative addition of nivolumab adds value in NSCLC

Related topics

ERS Congress 2024

Springer Medicine

Please log in to get access to this content

Related topics